The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.
A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...
Drugmakers Novo Nordisk and Eli Lilly and Company have transformed the landscape of chronic weight loss management with the ...
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...
So far, Tecvayli has had an incremental contribution to 2025 sales of $670M; while Darzalex Faspro saw $14.4B in 2025 sales.
The FDA has approved Eli Lilly's oral GLP-1, Foundayo. Let the heated rivalry with oral Wegovy begin
Eli Lilly announced this morning that the FDA has, as was expected, approved its oral GLP-1, orforglipron, as treatment for ...
12d
Viridian Therapeutics Shares Jump as REVEAL-1 Phase 3 Hits Primary Endpoint in Thyroid Eye Disease
Viridian Therapeutics (NASDAQ:VRDN) reported top-line results from its REVEAL-1 Phase III clinical trial evaluating ...
Health and wellness influencers are hawking unapproved treatments on the gray market. The future of the F.D.A.—and the health ...
Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the noninferiority bar against LHRH agonists.
The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...
Monthly injections of tonlamarsen lowered AGT but didn’t reduce BP in patients already on multiple antihypertensive drugs.
For patients with uncontrolled hypertension already on two or more medications, monthly injections of tonlamarsen (Kardigan) more effectively lowered plasma angiotensinogen (AGT) levels than a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results